Gordon Carl L's Form 4 filing
MBX Biosciences, Inc. (MBX) · filed Sep 17, 2024
- Accession no.
- 0000950170-24-107524
- Filed
- Sep 17, 2024
- Trade date
- Sep 16, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $12.0M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gordon Carl LCIK 0001282930 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | Common Stock | CConversionAcquired | +2,658,428 | –F1 | – | 2,658,428 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionAcquired | +403,787 | –F1 | – | 403,787 | Indirect | |
| Sep 16, 2024 | Common Stock | PPurchaseAcquired | +500,000 | $16.00 | +$8,000,000 | 3,158,428 | Indirect | |
| Sep 16, 2024 | Common Stock | PPurchaseAcquired | +250,000 | $16.00 | +$4,000,000 | 653,787 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | Common Stock | CConversionDisposed | −1,029,157 | –F1 | – | 0 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionDisposed | −1,629,271 | –F1 | – | 0 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionDisposed | −403,787 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
Referenced by the price of 2 transactions in Table I and 3 transactions in Table II.